Acteria Femina2.3 Billion

Acteria Femina is a multi-strain probiotic dietary supplement providing a combinedcount of approximately 2.3 billion colony-forming units (CFU) of live beneficial bacteria per dose.It is used to support gut microbiota balance and general digestive health.

Established / Guideline-Supported Uses

• Prevention of antibiotic-associated diarrhoea (AAD): When taken alongside antibiotictherapy (with dosing separated appropriately), certain probiotic strains have evidence supporting a reducedrisk of AAD, particularly in children and adults on broad-spectrum antibiotics.
• Adjunct management of acute infectious diarrhoea: May modestly reduce the duration ofacute watery diarrhoea in children and adults when used as an adjunct to standard oral rehydration therapy,not as a replacement for it.
• General maintenance of gut microbiota balance: Suited to lower-dose, maintenance-leveluse, including in paediatric populations, depending on the specific product and strains included.

Adjunct / Variable-Evidence Uses

• Symptomatic relief in irritable bowel syndrome (IBS) - evidence varies considerably by specific strainand is not consistent across all products.
• General digestive comfort (bloating, irregular bowel habit) as a dietary adjunct.

Evidence for benefit is strain-specific; effects seen with one probiotic strain or combination cannotbe assumed to apply to another. Acteria Femina is a supplement, not a substitute for prescribed medical treatmentof any diagnosed condition.

Probiotic Combination [2.3 Billion] is a multi-strain probiotic combination formulated to deliver a total of approximately2.3 billion CFU of live, freeze-dried beneficial bacteria per dose (capsule/sachet), as indicated on theproduct label. Common excipients in such formulations may include a prebiotic carrier (e.g. maltodextrinor inulin), stabilisers, and a capsule shell; exact strain composition and excipients vary by manufacturerand should be confirmed on the specific product packaging.

Acteria Femina is an oral multi-strain probiotic supplement. Probiotics are live microorganisms that, whenadministered in adequate amounts, confer a health benefit on the host by helping to maintain or restore afavourable balance of gut microbiota. Acteria Femina is formulated as a lower-CFU, maintenance-strength product(2.3 billion CFU), which makes it particularly suitable for general digestive health support and forpaediatric or lower-dose use, as opposed to high-CFU products intended for more intensive short-term use.

Acteria Femina belongs to the therapeutic class of Probiotics / Gut microbiota modifying agents, classified as a dietary/food supplement rather than a prescription pharmaceutical in most regulatory frameworks.

Mechanism of Action

Probiotic Combination [2.3 Billion] works through several complementary mechanisms typical of live-bacterial probiotic products:

• Competitive exclusion: Live strains compete with pathogenic organisms for adhesionsites on the intestinal mucosa and for nutrients, limiting pathogen colonisation.
• Production of antimicrobial metabolites: Some strains produce short-chain fatty acids,bacteriocins, or lactic acid that lower luminal pH and inhibit pathogenic bacterial growth.
• Mucosal barrier support: May help maintain tight-junction integrity of the intestinalepithelium.
• Immune modulation: Interacts with gut-associated lymphoid tissue, which may modestlymodulate local immune responses.

As a supplement rather than a systemically absorbed drug, Probiotic Combination [2.3 Billion] acts predominantly within thegastrointestinal lumen; live organisms are largely not absorbed into the systemic circulation inindividuals with normal gut and immune barrier function.

Acteria Femina is administered orally. Capsules should be swallowed whole with water; sachet formulations(if applicable) should be mixed with a small amount of cool or lukewarm (not hot) water or food immediatelybefore consumption, as heat and prolonged exposure can reduce viability of live organisms. If taken withantibiotics, administer Acteria Femina at least 2 hours apart from the antibiotic dose.

Clinically Significant Interactions

• Antibiotics/antimicrobials: Concurrent antibiotic therapy can kill the live bacteria inActeria Femina, reducing its effectiveness. Space administration of Acteria Femina by at least 2 hours from any antibioticdose (per product guidance) to minimise this effect. Acteria Femina is not an antibiotic and does not treat bacterialinfections itself.
• Immunosuppressive therapy: In patients on significant immunosuppressive treatment,theoretical increased risk of systemic infection with live probiotic organisms should be considered;see Contraindications and Precautions.

No clinically significant interactions with common non-antibiotic medications are well established forstandard multi-strain probiotic products, but any new supplement should be discussed with a physician orpharmacist, especially in patients on multiple medications.

Acteria Femina is generally well tolerated. Reported side effects include:

• Common: Mild, transient gastrointestinal gas, bloating, or a mild change in bowel habit,particularly during the first few days of use.
• Uncommon: Abdominal discomfort or mild nausea.
• Rare (mainly in immunocompromised or critically ill patients, or those with a central venouscatheter): Systemic infection (bacteraemia/fungaemia) related to translocation of live organisms -see Contraindications and Precautions.

Discontinue Acteria Femina and seek medical advice if fever, signs of infection, or persistent/worseninggastrointestinal symptoms develop.

Acteria Femina is generally considered low risk in pregnancy and breastfeeding, as live dietary probiotic strainsare not typically systemically absorbed in individuals with normal gut integrity. However, robustcontrolled trial data specific to Acteria Femina in pregnant or breastfeeding women is limited. As with anysupplement, Acteria Femina should be used during pregnancy or lactation only as directed on the product label orby a physician, with use only if clearly needed; a physician should be consulted before use, particularlyif there are additional risk factors such as immune compromise.

• Use Acteria Femina with caution, and only under medical supervision, in patients with severe immunocompromise,an indwelling central venous catheter, or critical illness, due to a rare risk of probiotic-related systemicinfection (see Contraindications).
• Discontinue Acteria Femina and seek prompt medical attention if fever or other signs of infection develop duringuse.
• Acteria Femina is not an antibiotic and must not be used as a substitute for prescribed antimicrobial therapy ofa diagnosed infection.
• If used alongside antibiotic therapy, separate dosing of Acteria Femina from the antibiotic by at least 2 hours,per product guidance, to preserve viability of the live organisms.
• Mild, self-limited gas or bloating may occur on initiation; this typically resolves with continued use.

Acteria Femina has a wide margin of safety, and significant toxicity from excess intake is not well documented inindividuals with normal immune function; the most likely effect of substantially exceeding the labelleddose is increased gastrointestinal gas, bloating, or loose stools. However, if a dose substantially largerthan recommended has been taken, or if any concerning symptoms (such as fever, severe abdominal pain, orsigns of infection) develop - particularly in an immunocompromised person, a person with a central venouscatheter, or a child - seek immediate medical attention or contact a poison control centre rather thanattempting home treatment.

Store at room temperature (below 30°C), away from direct light and moisture. Some formulations may recommend refrigeration once opened - check the specific product label. Keep out of reach of children.

Renal/Hepatic Impairment

No specific dose adjustment of Acteria Femina is established for renal or hepatic impairment; however, patientswith significant hepatic or other chronic illness causing immune compromise fall under the precautionsabove and should use Acteria Femina only under medical advice.

Elderly

Acteria Femina may be used in elderly patients at standard doses; no specific dose adjustment is established,though age-related immune changes should be considered per the precautions above.

Immunocompromised Patients

See Contraindications - use only under direct physician supervision, if at all.

Acteria Femina may be used short-term (e.g. for the duration of a course of antibiotics, to help reduce the riskof antibiotic-associated diarrhoea, continuing for a few days after the antibiotic course per productguidance) or longer-term for general maintenance of gut microbiota balance, depending on the indication andphysician or product-label advice. There is no well-established maximum duration of use for healthyindividuals using Acteria Femina for general digestive health maintenance, but periodic reassessment of ongoing needis reasonable.

Probiotic Combination [2.3 Billion] falls under the drug/product class: Probiotic supplements - multi-strain live bacterial combination products.

Probiotic Combination [2.3 Billion] exerts its effect through live multi-strain bacterial colonisation and activity within thegastrointestinal lumen, including competitive exclusion of pathogens, production of antimicrobialmetabolites (e.g. lactic acid, short-chain fatty acids, bacteriocins), support of intestinal epithelialbarrier integrity, and modulation of local gut-associated immune activity, collectively supporting afavourable gut microbiota balance.

Acteria Femina is formulated at a comparatively low CFU count (approximately 2.3 billion CFU), which makes itsuited to paediatric and lower-dose maintenance use, depending on the specific product's paediatric labelling.Use in children should follow the age- or weight-based dosing given on the product label. Safety andefficacy in neonates and very young infants have not been well established for most probiotic products,and a physician should be consulted before use of Acteria Femina in this age group, particularly in infants who arepreterm, low birth weight, or have an underlying immune or gastrointestinal disorder.